Latest Regulatory Challenges News

ALS Limited reported a robust FY25 with 16% revenue growth to AUD 3 billion, underpinned by strong organic expansion and key acquisitions. Despite slight NPAT decline, the company advances its sustainability agenda and invests in global lab upgrades.

PointsBet shareholders have voted in favour of the proposed $1.20 per share acquisition by MIXI, Inc, marking a significant premium and clearing a key hurdle ahead of court approval.

Collins Foods delivered resilient FY25 results with solid revenue growth and a strategic pivot towards German market expansion, while addressing profitability challenges in the Netherlands.

Collins Foods reported a record $1.52 billion revenue for FY25 with flat EBITDA despite tough market conditions, while signaling optimism for low to mid-teens NPAT growth in FY26.

Collins Foods Limited reported record revenue of $1.52 billion for FY25, up 2.1%, but statutory net profit plunged 88.5% due to significant impairments and wage provisions. The company declared a fully franked final dividend of 15 cents per share, signaling confidence despite challenges.

Fletcher Building unveiled a comprehensive strategic review and FY25 outlook at its Investor Day, highlighting a focus on manufacturing and distribution alongside significant restructuring costs. The company targets a leaner operation with disciplined capital management and a net debt goal of NZD 400m to 900m.

Renergen Limited reports steady LNG production despite maintenance downtime, progresses a strategic merger with ASP Isotopes, and advances exploration with new seismic data and drilling activity.

IperionX has secured its first U.S. Army task order worth $1.3 million under a $99 million SBIR Phase III contract, marking a significant step in reshoring titanium production for U.S. defense needs.

OD6 Metals has secured a second regulatory approval to extend its Phase 2 drilling at the historic Gulf Creek Copper Project, targeting promising repeat mineral structures and deepening exploration near recent high-grade intercepts.

Sunrise Energy Metals Limited has announced a $1.5 million Share Purchase Plan (SPP) offering eligible shareholders the chance to invest at 30 cents per share, accompanied by options exercisable at 40 cents until May 2027. The capital raise aims to fast-track the feasibility study and development of its Syerston Scandium Project in New South Wales.

Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.